Ifosfamide and DNA Damage in Children with Cancer
Author Information
Author(s): Willits I, Price L, Parry A, Tilby M J, Ford D, Cholerton S, Pearson A D J, Boddy A V
Primary Institution: Northern Institute for Cancer Research, University of Newcastle
Hypothesis
The degree of DNA damage following ifosfamide treatment may be linked to its therapeutic efficacy.
Conclusion
Fractionated dosing of ifosfamide results in greater DNA damage compared to continuous infusion, suggesting a potential increase in therapeutic efficacy.
Supporting Evidence
- DNA damage was measured using the alkaline COMET assay.
- Elevations in DNA damage were observed in all patients after ifosfamide administration.
- The degree of DNA damage increased to a peak at 72 hours post-treatment.
- Patients receiving fractionated dosing had more DNA damage than those receiving continuous infusion.
- There was a good correlation between the area under the curve of ifosfamide and the cumulative percentage of cells with DNA damage.
Takeaway
This study looked at how a cancer drug called ifosfamide affects DNA in kids with cancer. They found that giving the drug in smaller doses over a few days caused more DNA damage than giving it all at once, which might help the drug work better.
Methodology
The study involved 19 pediatric patients receiving ifosfamide, with DNA damage assessed using the COMET assay and pharmacokinetics analyzed through blood samples.
Limitations
The study had a heterogeneous patient population and did not analyze the relationship between DNA damage and toxicity due to insufficient numbers.
Participant Demographics
19 patients (5 female), aged 2 to 19 years, mostly with rhabdomyosarcoma or Ewing's sarcoma.
Statistical Information
P-Value
0.004
Statistical Significance
p=0.004
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website